Open AccessReassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?
Author(s) -
Felicia Cosman,
Jane A. Cauley,
Richard Eastell,
Steven Boonen,
Lisa Palermo,
Ian R. Reid,
Steven R. Cummings,
Dennis M. Black
Publication year - 2014
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2014-1971
Subject(s) - zoledronic acid , medicine , incidence (geometry) , randomization , placebo , clinical trial , femoral neck , surgery , osteoporosis , mathematics , alternative medicine , pathology , geometry
Data are needed to guide therapeutic decisions about stopping bisphosphonates after an initial treatment period.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom